Short answer: MOS (mannan-oligosaccharides) is a prebiotic ingredient derived from the cell wall of Saccharomyces cerevisiae yeast. The cell wall is composed primarily of mannoproteins (mannose-rich glycoproteins on the outer surface) and beta-glucans (the inner structural layer). Per Stuyven 2009 (Vet Immunol Immunopathol) and Newman 1994, MOS works through two distinct mechanisms — pathogen binding via Type 1 fimbriae interactions and immune modulation via innate-immune cell receptors. Per Spring 2000 (Poult Sci) and Pascher 2008 (Arch Anim Nutr), MOS supplementation at 0.1–0.4% dry matter modulates microbiome stability and IgA in dogs and other companion animals. Per AAHA 2022 GI consensus, the canine evidence is supportive. The KibbleIQ rubric awards prebiotic-positive credit when MOS appears on the label, particularly in combination with named-strain probiotics.

The chemistry — yeast cell wall structure and MOS production

The Saccharomyces cerevisiae yeast cell wall is a layered structure approximately 100–200 nm thick, composed of approximately 30–50% beta-glucans (the inner structural layer providing rigidity), 30–50% mannoproteins (the outer layer providing surface chemistry and pathogen-recognition properties), 1–3% chitin (a structural polymer), and trace lipids. The mannoproteins are heavily glycosylated proteins where mannose chains extend outward from the protein backbone. Per Aldrich 2006 (Petfood Industry) review, MOS is produced by enzymatic or autolytic disruption of brewer’s yeast cell walls, separation and purification of the mannan-rich outer fraction, and drying to a stable powder for pet-food incorporation.

The two pet-food MOS supply pathways are post-fermentation brewer’s yeast (a byproduct of beer brewing) and dedicated S. cerevisiae yeast cultures grown specifically for cell wall extraction. The dedicated-culture approach yields more consistent MOS content but at higher cost; brewer’s-yeast-derived MOS is the more common pet-food source. AAFCO 2024 recognizes MOS as “Yeast Cell Wall Extract” (Saccharomyces cerevisiae) under the broader yeast products ingredient framework. See our brewers yeast explainer and nutritional yeast explainer for the related yeast-product categories that differ in target ingredient (whole-cell vs cell-wall vs nutrient-rich nutritional yeast).

Pathogen-binding mechanism — the Stuyven 2009 reference

Per Newman 1994 (Biotechnology in the Feed Industry) and Stuyven 2009 (Vet Immunol Immunopathol), the principal pathogen-binding mechanism of MOS operates through Type 1 fimbriae interactions. Type 1 fimbriae are surface appendages on certain pathogenic bacteria including Escherichia coli, Salmonella enterica, and Klebsiella pneumoniae. The fimbriae carry mannose-binding lectins on their tips, which the bacteria use to attach to mannose residues on intestinal epithelial cells. The attachment is the first step of intestinal colonization and infection.

MOS in the gut lumen presents an excess of mannose residues that competitively bind the bacterial fimbriae, redirecting the pathogens away from the intestinal wall. The bound bacteria are then carried out of the gut in normal stool flow rather than colonizing. Per Stuyven 2009 canine immune-modulation study, oral MOS at 0.1–0.4% of dry matter reduced fecal pathogen counts and raised systemic IgA over 14–28 days. Per Cox 2010 (Poult Sci) avian challenge study, MOS supplementation reduced Salmonella colonization in challenged poultry models — the most-replicated MOS effect across companion-animal and food-animal species.

Immune modulation — the Spring 2000 framework

The second MOS mechanism operates through immune-cell receptors recognizing beta-glucans and mannoproteins as pathogen-associated molecular patterns (PAMPs). Per Spring 2000 (Poultry Science) review and Vetvicka 2014 (Annals Translational Med) review, beta-glucans bind to Dectin-1 and complement receptor 3 on macrophages and dendritic cells, triggering downstream innate-immune signaling cascades. The downstream effects include increased phagocyte activity, modulated cytokine release, and adaptive-immune priming.

The clinical relevance: per Stuyven 2009, oral MOS at 0.1–0.4% dry matter raised serum IgA in dogs — an indirect indicator of mucosal immunity activation. Per Pascher 2008 (Arch Anim Nutr) canine MOS supplementation trial, fecal microbiome stability improved and pathogen-class counts (Clostridium, Enterobacteriaceae) decreased over 28 days. Per AAHA 2022 GI consensus, MOS carries low-to-moderate evidence for canine GI support, comparable to FOS and inulin in evidence rating but operating through complementary rather than overlapping mechanisms.

How MOS differs from FOS, inulin, and other prebiotics

Per the prebiotic-mechanism framework, MOS is principally a binding-and-modulating prebiotic, while FOS, inulin, and beet pulp are principally fermentable-fiber prebiotics. The functional differences: FOS / inulin / beet pulp ferment to short-chain fatty acids that fuel colonocytes (per Sunvold 1995) and acidify the colonic lumen. MOS does not significantly ferment in the colon — it operates by binding pathogens at Type 1 fimbriae sites and by modulating innate-immune signaling. The two mechanisms are complementary, not overlapping.

The pet-food formulation pattern: MOS is often used in combination with FOS, inulin, or beet pulp to deliver both the pathogen-binding effect and the SCFA-fermentation effect from a single product. Veterinary therapeutic GI diets (per AAVCN 2024 Veterinary Therapeutic Diets) often contain MOS at 0.1–0.3% alongside named-strain probiotics (Bifidobacterium animalis, Lactobacillus acidophilus, or Enterococcus faecium SF68 per Bybee 2011 JVIM) and additional fermentable prebiotic fiber. See our FOS explainer, inulin explainer, prebiotics explainer, and beet pulp explainer.

How KibbleIQ scores MOS

The KibbleIQ Dry Kibble Rubric awards prebiotic-positive credit when MOS appears on the label, recognized as “Yeast Cell Wall Extract,” “Mannan-Oligosaccharides,” or “Saccharomyces cerevisiae extract” per AAFCO 2024 ingredient definitions. The rubric does not require MOS at the Stuyven 2009 effective dose threshold (0.1–0.4% dry matter) for credit because pet food labels rarely declare prebiotic percentages and rubric scoring works from label-derived signals.

The rubric awards higher GI-support credit when MOS appears alongside complementary prebiotics (FOS, inulin, beet pulp) and named-strain probiotics — the formulation pattern most consistent with AAHA 2022 GI consensus and AAVCN 2024 Veterinary Therapeutic Diet conventions. Foods using MOS as the only labeled GI-support ingredient earn label-positive credit but not therapeutic-tier credit. For dogs with chronic enteropathy, post-antibiotic GI recovery, or recurrent E. coli or Salmonella-associated GI signs, the actionable rubric guidance is to look for MOS + FOS + named-strain probiotic combinations or veterinary therapeutic diets with full microbiome-support formulation. See best dog food for sensitive stomachs. To check your dog’s food, paste the ingredient list into the KibbleIQ analyzer.